Floatz logo

Binimetinib

Recurrent Ovarian Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
81/ 100

Competitive context

53 Active assets in the Recurrent Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Yonsei University
Phase 4BBB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 4BBB
Olaparib
Imunon
Phase 4BB
Palbociclib
University Medical Center Groningen
Phase 4BB
Vinorelbine
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Binimetinib is also rated in:

metastatic malignant neoplasm in the colonDormant
BB
Indicative ·
70 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
68 / 100
View asset →
triple-negative breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →